摘要
目的探寻近年来国内门诊肝病辅助用药使用情况,分析并提出建议。方法抽取2015年—2019年我国6座城市85家医院含有肝病辅助用药的门诊处方数据,使用真实世界数据分析的方法对肝病辅助用药处方的付费方式、开具科室、药品类别和用药情况进行分析。结果共提取处方数据1113575张,涉及复方甘草酸苷、多烯磷脂酰胆碱、双环醇等38种肝病辅助用药。肝病辅助用药使用以三级医院为主,开具肝病辅助用药最多的科室包括感染科、消化内科和结核科。以抗炎类肝病辅助用药处方量占比最高,具体品种以复方甘草酸苷、多烯磷脂酰胆碱和双环醇最多。253429张处方(占处方总量的22.76%)存在多种肝病辅助用药物联合使用情况,联用数量最多达6种,其中以多烯磷脂酰胆碱联合双环醇的占比最高。结论我国门诊患者肝病辅助用药物用量较大,目前临床应用合理性较好,但仍存在合并用药多等问题有待解决。
Objective To investigate the use of hepatoprotective drugs in China in recent years,and to put forward related suggestions.Methods The outpatient prescription data of hepatoprotective drugs were collected from 85 hospitals in 6 cities of China from 2015 to 2019,and a real-world data analysis was performed to analyze the payment method,issuing department,drug category,and use of hepatoprotective drugs.Results A total of 1113575 prescriptions were extracted,involving 38 hepatoprotective drugs such as compound glycyrrhizin,polyene phosphatidylcholine,and bicyclol.Hepatoprotective drugs were mainly in tertiary hospitals,and the highest number of prescriptions containing hepatoprotective drugs were observed in department of infectious diseases,department of gastroenterology,and department of tuberculosis.Anti-inflammatory hepatoprotective drugs accounted for the highest proportion of all prescriptions,mainly compound glycyrrhizin,polyene phosphatidylcholine,and bicyclol.Of all prescriptions,253429(22.76%)had the combination of multiple hepatoprotective drugs,with the highest number of 6 drugs,among which polyene phosphatidylcholine combined with bicyclol accounted for the highest proportion.Conclusion There are large quantities of hepatoprotective drugs used by outpatients in China.At present,the hepatoprotective drugs are clinically applied rationally,but there are still some problems to be solved,such as the combination of drugs.
作者
赵紫楠
吕俊玲
杨蕾
张亚同
ZHAO Zinan;LYU Junling;YANG Lei;ZHANG Yatong(Department of Pharmacy,National Center of Gerontology,Beijing Hospital,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Assessment of Clinical Drugs Risk and Individual Application Key Laboratory,Beijing 100730,China;Clinical Trial Center,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Science,Beijing 100730,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2021年第11期2595-2599,共5页
Journal of Clinical Hepatology
基金
国家重点研发计划(2020YFC2008301,2020YFC2009001)
“国家重大新药创制”科技重大专项(2017zx09101001)。
关键词
肝病辅助用药
药物处方
真实世界数据
Hepatoprotective Drugs
Drug Prescriptions
Real-World Data
